Abbisko Cayman Limited (2256.HK) AI-Powered Stock Analysis
See how Abbisko Cayman Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
2256.HK●HKSE
HealthcareBiotechnology
HK$9.36
HK$0.45(4.59%)
Hong Kong Market opens in 38h 18m
Advertisement
Abbisko Cayman Limited (2256.HK)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerAbbisko Cayman Limited (2256.HK) Stock Overall Grade
Abbisko Cayman Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Abbisko Cayman Limited's overall stock rating.
Forecast
B+Score
72/100Financial Growth
CScore
40/100Fundamental Growth
CScore
43/100Key Ratios
B+Score
76/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Abbisko Cayman Limited (2256.HK) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 72/100 (B+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (43/100, C) highlight its stability, while Key Ratios (76/100, B+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Abbisko Cayman Limited stock grade, including financials, comparisons, and forecasts.